Globe Net Wireless Corp. (OTCMKTS: GNTW) isn’t your typical reverse merger deal because the acquiring asset has a solid base of revenue. The company reversing into GNTW is called Stemtech Corp and it is a direct-to-consumer-based business with nutraceutical products capable of releasing the number of adult stem cells circulating in our system allowing us to unlock rejuvenating healing pathways.
The company was founded in 2005 and had exponential growth until 2017 when its run rate was close to $75 million annually. Internal conflicts derailed this highly successful business with over 200,000 distributors. Strategic investors familiar with the business took over custodianship to restructure the company. The restructuring took much longer than anticipated, but demand for the product was so high amongst core consumers that it still generated close to $5.0 million annually. Stemtech has a proven business model with infrastructure in place, a core following of distributors, and a uniquely well-positioned product offering in a fast-growing industry.
Understanding Stem Cells
Some investors might be wary of anything related to biotech so for those investors, it’s essential to have a baseline understanding of the topic. Over the past decade, what has been sensationalized in the news about stem cells pertains to the use of embryonic stem cells (ESC’s). This controversy is divided along moral lines primarily regarding the research of ESC’s versus adult stem cells. The good news is that the focus of this article is on adult stem cells, the other class of stem cells, and steers clear of any of the controversial research. There is a mountain of research focused on adult stem cells that supports their use in a variety of diseases and tissue regeneration.